Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

BACKGROUND: The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. METHODS: Given the high degree of genetic heterogeneity in melanoma, we sought to understand the breadth of variation in PI3K signalling in the large NZM panel of early passage cell lines developed from...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Khanh B., Kolekar, Sharada, Jabed, Anower, Jaynes, Patrick, Shih, Jen-Hsing, Wang, Qian, Flanagan, Jack U., Rewcastle, Gordon W., Baguley, Bruce C., Shepherd, Peter R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866738/
https://www.ncbi.nlm.nih.gov/pubmed/33549048
http://dx.doi.org/10.1186/s12885-021-07826-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866738/
https://www.ncbi.nlm.nih.gov/pubmed/33549048
http://dx.doi.org/10.1186/s12885-021-07826-4

Ejemplares similares